Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: Data from the Netherlands

Current Medical Research and Opinion

Volumn 26, Issue 11, 2010, Pages 2565-2574

  Sasané, Rahul ^a   Hodgkins, Paul ^a   Meijer, Willemijn ^b,c  

^a SHIRE   (United States)

^b PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ADHD; Atomoxetine; Drug utilization; Methylphenidate; Netherlands; Stimulant; Treatment stabilization

Indexed keywords

ATOMOXETINE; DEXAMPHETAMINE; LONG ACTING DRUG; METHYLPHENIDATE;

ADOLESCENT; ADOLESCENT DISEASE; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILDHOOD DISEASE; CONTROLLED RELEASE FORMULATION; DRUG UTILIZATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; COHORT STUDIES; FEMALE; HUMANS; MALE; MEDICAL AUDIT; METHYLPHENIDATE; NETHERLANDS; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICIAN'S PRACTICE PATTERNS; PROPYLAMINES; RETROSPECTIVE STUDIES;

EID: 77958114294     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.518131     Document Type: Article

References (40)

1. Guevara J, Lozano P, Wickizer T, et al. Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:71-8
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Text Revision. 2000
3. Rucklidge JJ. Gender differences in attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2010;33:357-73
4. Faraone SV, Sergeant J, Gillberg C, et al. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003;2:104-13
5. Skounti M, Philalithis A, Galanakis E. Variations in prevalence of attention deficit hyperactivity disorder worldwide. Eur J Pediatr 2007;166:117-23
6. Polanczyk G, Silva de Lima M, Lessa Horta B, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942-8
7. Manos MJ. Pharmacologic treatment of ADHD: road conditions in driving patients to successful outcomes. Medscape J Med 2008;8:10-5
8. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007; 190:402-9
9. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-23
10. Preuss U, Ralston SJ, Baldursson G, et al. Study design, baseline patients characteristics and intervention in a cross-cultural framework: results from the ADORE study. Eur Child Adolesc Psychiatry 2006;15(Suppl 1):I4-14
11. Purper-Ouakil D, Cortese S, Wohl M, et al. Predictors of diagnostic delay in a clinical sample of French children with attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 2007;16:505-9
12. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005;366:237-48
13. Brown RT, Amler RW, Freeman WS, et al. American Academy of Pediatrics Committee on Quality Improvement; American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder. Treatment of attention-deficit/ hyperactivity disorder: overview of the evidence. Pediatrics 2005;115:e749-57
14. May DE, Kratochvil CJ. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. Drugs 2010;70:15-40.
15. Gibson AP, Bettinger TL, Patel NC, et al. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharamcother 2006; 40:1134-42
16. Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008;165:721-30
17. Newcorn JH, Sutton VK, Weiss MD, et al. Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. J Am Acad Child Adolesc Psychiatry 2009;48:511-18
18. Olfson M, Marcus S, Wan G. Stimulant dosing for children with ADHD: a medical claims analysis. J Am Acad Child Adolesc Psychiatry 2009;48:51-9
19. Taylor E, Dopfner M, Sergeant J, et al. European clinical guidelines for hyper-kinetic disorder-first upgrade. Eur Child Adolesc Psychiatry 2004;13 (Suppl 1):17-30
20. Vitiello B, Severe JB, Greenhill LL, et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry 2001;40:188-96
21. Vitiello B, Abikoff HB, Chuang SZ, et al. Effectiveness of methylphenidate in the 10-month continuation phase of the preschoolers with attention-deficit/ hyperactivity disorder treatment study (PATS). J Child Adolesc Psychopharmcol 2007;17:593-604
22. Faber A, Van Agthoven M, Kalverdijk LJ, et al. Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate. A study of cost-effectiveness in The Netherlands. CNS Drugs 2008;22:157-70
23. Christensen L, Sasané R, Hodgkins P, et al. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder. Curr Med Res Opin 2010;26:977-89
24. Herings RMC, Bakker A, Stricker BH, et al. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992;46:136-40
25. Herings RMC. The PHARMO System. CNS Spectr 2007;9(Suppl 16):14-7
26. Van Herk-Sukel MP, Van de Poll-Franse LV, Lemmens VE, et al. New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer 2009;46:395-404
27. Steele M, Weiss M, Swanson J, et al. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 2006;13:e50-62
28. Pliszka S and the AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894-921
29. American Academy of Pediatrics. Clinical practice guideline: treatment of the school-age child with attention-deficit/hyperactivity disorder. Pediatrics 2001;4:1033-44
30. Methylphenidate Summary of Product Characteristics (The Netherlands). Available at: http://db.cbg-meb.nl/IB-teksten/h03957.pdf. Accessed August 2009
31. Faber A, Kalverdijk LJ, De Jong-van Berg LT, et al. Parents' report on stimulant-treated children in the Netherlands: initiation of treatment and follow-up care. J Child Adolesc Psychopharmacol 2006;16:432-40
32. Atomoxetine Prescribing Information. Available at: http://pi.lilly.com/ us/strat-tera-pi.pdf. Accessed November 2009
33. Concerta Prescribing Information. http://www.concerta.net/assets/ Prescribing-Info-short.pdf. Accessed November 2009
34. Solhkhah R, Wilens TE, Daly J, et al. Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactiv-ity disorder and mood disorders. J Child Adolesc Psychopharmacol 2005; 15:777-86
35. Sasané R, Hodgkins P, Christensen L, Harley C. Daily average consumption and ADHD pharmacy costs in adult patients with ADHD prescribed long-acting medications. In preparation
36. Anney RJ, Lasky-Su J, O'Dú shláine C, et al. Conduct disorder and ADHD: evaluation of conduct problems as a categorical and quantitative trait in the international multicentre ADHD genetics study. Am J Med Genet B Neuropsychiatr Genet 2008;147B:1369-78
37. Leibson CL, Long KH. Economic implications of attention-deficit hyper-activity disorder for healthcare systems. PharmacoEconomics 2003;21: 1239-62
38. Faber A, Kalverdijk LJ, Lolkje TW, et al. Parents report on stimulant-treated children in The Netherlands: initiation of treatment and follow-up care. J Child Adolescent Psychopharmacol 2006;16:432-40
39. Volkers AC, Heerdink ER, Van Dijk L. Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001-2005). Pharmacoepidemiol Drug Saf 2007;16:1054-62
40. Hakkaart-van Roijen L, Zwirs BW, Bouwmans C, et al. Societal costs and quality of life of children suffering from attention deficit hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry 2007;16:316-26